MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1. Consent to Participate In A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
CONTINUATION: page 4 of page 
the IL-2 every eight hours until the maximum safe amount has been given. 
After approximately one week of recovery, a repeat treatment will be given 
using cells left over from the first week of treatment (if available) and more 
IL-2. It should be emphasized that the IL-2, the gene-m odified tumor cells 
and the TIL are all investigational agents. Approximately five weeks after 
that the effects of the treatment on your tumor will be measured by 
examination and x-rays. The treatment may be repeated if frozen lymphocytes 
are available or additional sites of tumor can be removed and new lymphocytes 
grown. To give you the cells and IL-2 we will place a catheter in a vein in 
your upper chest wall or your neck. This catheter will be used to give the 
lymphocytes and can remain in place for the duration of your therapy. 
Placement of these catheters may be performed in the Surgical Intensive Care 
Unit. It is remotely possible that we might cause a small hole in the lung as 
we insert the catheter. This may require putting a tube in the chest for 
several days. The catheter may beco me infected. Appropriate treatment will 
,be given if this occurs. 
Interleukin-2 . 
Interleukin-2 can cause side effects that include weight gain due to 
retention of as much as 20 lbs of fluid over the course of a week. The weight 
gain can cause your arms and legs to swell and fluid to accumulate in the 
lungs. This can cause shortness of breath and may require placement of a tube 
in your windpipe (trachea) to allow mechanical breathing (breathing assisted 
by a machine). This would require transfer to the Surgical Intensive Care 
Recombinant DNA Research, Volume 15 
I 
[130] 
